November 28, 2005 / Research Triangle Park, NC; Burlington, VT — Clinipace, Inc., a software company focused on late-stage clinical research studies and registries, and the Pediatric Inflammatory Bowel Disease Network for Research and Improvement (PIBDNet) announced today the launch of the new expanded PIBDNet Patient Registry supported by Clinipace’s software platform for clinical research and quality improvement programs – Tempo.
In partnership with the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), the Center for Children’s Healthcare Improvement, and the American Board of Pediatrics, the new expanded PIBDNet Registry is designed to monitor children and adolescents with inflammatory bowel disease (IBD) in an effort to better understand this debilitating disease, methods of prevention and treatment, and ultimately improve care for those suffering from IBD.
According to Dr. Richard Colletti, Principal Investigator of the PIBDNet Registry and Vice Chair of the Department of Pediatrics at the University of Vermont and Associate Chief of Vermont Children’s Hospital, Clinipace’s web-based platform – Tempo – will enable the expansion of the registry to hundreds of physicians nationwide because it is scalable and easy to use.
“Due to the success of the initial phase of the PIBDNet Registry, which included over 200 participating physicians, we have many more physicians interested in participating and now need a more robust technology solution to support the program going forward. With Tempo’s innate flexibility and ease-of-use, we were able to quickly transition our original registry to the Tempo platform, and are ready to enroll new physicians,” commented Dr. Colletti.
Dr. Colletti further explains the expansion goal: “We have received such enthusiastic response and support from our network of investigators that we are extending an invitation to all pediatric gastroenterologists in North America to join the network. Our hope is this widespread collaboration will lead to knowledge sharing that will dramatically reduce the morbidity of children with IBD.”
There are more than 900 pediatric gastroenterologists in the U.S. and Canada who treat IBD. Crohn’s disease and ulcerative colitis, the two most common forms of IBD can be seriously debilitating, resulting in nutritional problems and even slowed growth in children. IBD is primarily a disease of adolescents and young adults, affecting as many as 1 million Americans, 10% of whom are estimated to be children under the age of 18.
“Supporting research and collaboration among hundreds of physicians to combat IBD is something we are proud to be a part of,” said Jeff Williams, CEO of Clinipace. “Not only is it a great example of how our technology plays a role in understanding disease, but reinforces why we are in this business – to help those who help people live healthier lives.”
Clinipace is a clinical research software company providing a single, integrated data capture and study management platform for post-approval research and registries conducted by biopharmaceutical and medical device companies, Clinical Research Organizations (CROs) and Academic Medical Centers (AMCs). Our platform, called Tempo, is delivered via a web-based, on-demand architecture that streamlines the clinical research process by eliminating the integration headaches associated with multiple platforms, reducing project efforts and costs from startup to conclusion, and empowering project stakeholders to make informed real-time decisions regarding their research.
The mission of PIBDNet, the Pediatric IBD Network for Research and Improvement, is to build the foundation of a sustainable collaborative network where all pediatric gastroenterologists in North America can work together in a compelling process of continuous quality improvement and acquisition of new knowledge that will over the next decade dramatically reduce the morbidity of children with IBD. PIBDNet is supported by a grant from NASPGHAN with funds from the American Board of Pediatrics.